Reinventing Liposome Manufacturing: A Powder-First Platform for Stability, Scalability and Sustainability
LipoActive has fundamentally redesigned liposome manufacturing by replacing conventional high-stress, liquid-based production with a proprietary powder-first platform that enables gentle, controlled self-assembly upon hydration. By eliminating high shear, excessive heat and solvent-dependent processing, our technology dramatically improves stability, protects sensitive actives, enhances batch consistency and reduces environmental and logistical burdens. This is not a formulation tweak, it is a structural reinvention of how liposomes are manufactured at scale. LipoActive’s process sets a new benchmark for stability, scalability and sustainability in advanced delivery systems, representing a genuine step change in high-performance active manufacturing.
Redefining Liposome Manufacturing from First Principles
Liposomes have long been recognised as powerful delivery systems for sensitive and high-value actives. Yet the way they are traditionally manufactured has remained largely unchanged for decades, relying on heat, shear, pressure, and organic solvents to force lipids into structure.
The industry adapted to the limitations of these processes rather than solving them. LipoActive was founded on the belief that liposome manufacturing should work with chemistry, not against it.
Our innovation is not a minor optimisation. It is a fundamental redesign of how liposomes are formed, stabilised and delivered at manufacturing scale.
The Problem with Conventional Liposome Manufacturing
Traditional liquid-based liposome production presents persistent and widely accepted challenges:
• Exposure of sensitive actives to heat, pressure and shear
• Oxidation risks and hydrolytic instability in aqueous systems
• Batch-to-batch variability driven by process intensity
• Energy-heavy production requirements
• Complex cold-chain logistics
• Limited shelf-life stability in liquid form
These constraints restrict formulation freedom and reduce the viability of high-value, labile ingredients such as peptides, growth factors, botanicals and antioxidants.
Instead of accepting these compromises, we asked a simple question:
What if liposomes could be manufactured in a way that inherently protects actives rather than stressing them?
Stage One: EncapSure™ — Controlled Liposome Formation
EncapSure™ was LipoActive’s first breakthrough. A proprietary refinement of the liposome formation environment.
Rather than forcing lipid assembly through aggressive mechanical energy, the EncapSure™ process uses a calmer, controlled microenvironment that allows lipid bilayers to form predictably and consistently.
This approach delivers:
• Reduced exposure of actives to thermal and mechanical stress
• Improved uniformity of vesicle formation
• Enhanced reproducibility and batch reliability
• Greater control over encapsulation efficiency
EncapSure™ demonstrated that high performance does not require high aggression. It proved that a more elegant, chemistry-led process could outperform force-driven systems.
But this was only the beginning.
The Breakthrough Insight: Eliminate the Liquid Constraint
While refining EncapSure™, we identified a deeper systemic limitation:
The instability of liposomes is not simply a processing problem, it is a format problem.
Conventional manufacturing forms liposomes in aqueous environments, then attempts to stabilise them. But liquids inherently introduce:
• Oxidation pathways
• Hydrolytic degradation
• Microbial susceptibility
• Transportation inefficiencies
• Refrigeration dependency
We challenged the assumption that liposomes must be manufactured and stored as liquids. This shift in thinking led to our most significant innovation.
The Powder-First Manufacturing Process
LipoActive developed a proprietary powder-first liposome manufacturing platform.
Instead of creating liposomes in liquid and trying to preserve them, we manufacture a dry, stable powder containing all structural components required for liposome formation.
When hydrated, liposomes self-assemble under gentle, controlled conditions, without high shear, high heat, or aggressive solvents.
Key Advantages
1. Dramatically Enhanced Stability
The dry format significantly reduces oxidation and hydrolytic degradation, extending shelf life and protecting sensitive actives.
2. Reduced Process Stress
No reliance on high shear homogenisation or thermal forcing. Sensitive peptides, botanicals and antioxidants experience minimal processing damage.
3. Improved Scalability and Consistency
Dry processing allows tighter environmental control and reduces variability inherent in liquid systems.
4. Energy and Environmental Efficiency
Lower energy inputs compared to heat- and shear-intensive methods. Reduced cold-chain requirements during storage and distribution.
5. Formulation Flexibility
Customers can hydrate at point of manufacture, enabling multiple product formats from a single stable intermediate.
Manufacturing Innovation, Not Just Formulation Innovation
Many liposome innovations focus on novel ingredients. LipoActive’s innovation sits deeper in the manufacturing architecture itself.
We have:
• Reengineered the formation pathway
• Removed unnecessary process stress
• Challenged the liquid-first paradigm
• Created a modular, scalable dry platform
This represents a step-change in how liposomal systems can be manufactured.
Rather than adding complexity, we simplified the process by removing its most destabilising element: water during manufacture and storage.
Built Through Engineering Discipline and Persistence
This innovation was not the result of a single discovery. It required years of:
• Iterative prototyping
• Materials science refinement
• Process parameter optimisation
• Stability testing and validation
• Manufacturing design engineering
Participation in a Cambridge accelerator sharpened our commercial strategy, but the scientific and engineering progress was driven by disciplined experimentation and a willingness to rethink long-standing industry norms.
Commercial and Industry Impact
The implications of this manufacturing model are significant:
• Enables viable liposomal delivery of previously unstable actives
• Expands application potential across pharma, nutraceutical and advanced skincare sectors
• Reduces logistics and storage complexity
• Improves sustainability profile of liposome production
• Enhances reproducibility — critical for regulated markets
As demand increases for clean-label, stable and high-performance delivery systems, manufacturing reliability becomes a competitive advantage.
LipoActive delivers that reliability at the process level.
Why LipoActive Deserves the Innovation in Manufacturing Award
The Innovation in Manufacturing Award recognises breakthroughs that improve not just products, but how products are made.
LipoActive has:
• Rethought liposome production from first principles
• Replaced force-driven assembly with controlled formation
• Transitioned from unstable liquid manufacturing to a stable powder-first platform
• Delivered measurable improvements in stability, consistency and environmental efficiency
• Created a scalable manufacturing solution aligned with the future of high-value actives
This is not incremental improvement.
It is structural redesign.
By eliminating unnecessary stress, reducing instability at its source, and introducing a fundamentally different manufacturing format, LipoActive sets a new benchmark for how liposomal systems can be produced at scale.
We believe this represents precisely the type of forward-thinking, practical, industry-shaping innovation that the MakingPharma Innovation in Manufacturing Award was created to recognise.
